103 related articles for article (PubMed ID: 27884075)
1. SRM-based measurements of proprotein convertase subtilisin/kexin type 9 and lipoprotein(a) kinetics in nonhuman primate serum.
Xie F; Emery MG; Gibbs JP; Rock DA; Rock BM
Bioanalysis; 2016 Dec; 8(24):2551-2563. PubMed ID: 27884075
[TBL] [Abstract][Full Text] [Related]
2. PCSK9 Association With Lipoprotein(a).
Tavori H; Christian D; Minnier J; Plubell D; Shapiro MD; Yeang C; Giunzioni I; Croyal M; Duell PB; Lambert G; Tsimikas S; Fazio S
Circ Res; 2016 Jun; 119(1):29-35. PubMed ID: 27121620
[TBL] [Abstract][Full Text] [Related]
3. PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.
Croyal M; Tran TT; Blanchard RH; Le Bail JC; Villard EF; Poirier B; Aguesse A; Billon-Crossouard S; Ramin-Mangata S; Blanchard V; Nativel B; Chemello K; Khantalin I; Thedrez A; Janiak P; Krempf M; Boixel C; Lambert G; Guillot E
Clin Sci (Lond); 2018 May; 132(10):1075-1083. PubMed ID: 29724769
[TBL] [Abstract][Full Text] [Related]
4. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
5. A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts.
Gauthier MS; Pérusse JR; Awan Z; Bouchard A; Tessier S; Champagne J; Krastins B; Byram G; Chabot K; Garneau P; Rabasa-Lhoret R; Faubert D; Lopez MF; Seidah NG; Coulombe B
Methods; 2015 Jun; 81():66-73. PubMed ID: 25770357
[TBL] [Abstract][Full Text] [Related]
6. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese.
Yang SH; Li S; Zhang Y; Xu RX; Zhu CG; Guo YL; Wu NQ; Qing P; Gao Y; Cui CJ; Dong Q; Sun J; Li JJ
J Endocrinol Invest; 2016 Aug; 39(8):875-83. PubMed ID: 26894681
[TBL] [Abstract][Full Text] [Related]
8. Circulating Complex of Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 in the Serum Measured by ELISA.
Razova OA; Afanas'eva OI; Egiazaryan MG; Sherstyuk EE; Klesareva EA; Pokrovskii SN
Bull Exp Biol Med; 2020 Sep; 169(5):639-643. PubMed ID: 32979126
[TBL] [Abstract][Full Text] [Related]
9. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.
Chan DC; Wong AT; Pang J; Barrett PH; Watts GF
Clin Sci (Lond); 2015 Mar; 128(6):379-85. PubMed ID: 25291660
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of an aptamer for use as an affinity reagent with MS: PCSK9 as an example protein.
Gupta V; Lassman ME; McAvoy T; Lee AY; Chappell DL; Laterza OF
Bioanalysis; 2016 Aug; 8(15):1557-1564. PubMed ID: 27397798
[TBL] [Abstract][Full Text] [Related]
11. Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.
Peng K; Xu K; Liu L; Hendricks R; Delarosa R; Erickson R; Budha N; Leabman M; Song A; Kaur S; Fischer SK
MAbs; 2014; 6(6):1500-8. PubMed ID: 25484037
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 and Lp(a) levels of children born after assisted reproduction technologies.
Vlachopoulos C; Kosteria I; Sakka S; Gkourogianni A; Terentes-Printzios D; Koutagiar I; Skoumas I; Miliou A; Papassotiriou I; Gardikioti V; Loutradis D; Chrousos G; Kanaka-Gantenbein C; Tousoulis D
J Assist Reprod Genet; 2019 Jun; 36(6):1091-1099. PubMed ID: 31079266
[TBL] [Abstract][Full Text] [Related]
13. Practical immunoaffinity-enrichment LC-MS for measuring protein kinetics of low-abundance proteins.
Lassman ME; McAvoy T; Lee AY; Chappell D; Wong O; Zhou H; Reyes-Soffer G; Ginsberg HN; Millar JS; Rader DJ; Gutstein DE; Laterza O
Clin Chem; 2014 Sep; 60(9):1217-24. PubMed ID: 24751376
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
Circ J; 2016; 80(2):512-8. PubMed ID: 26632531
[TBL] [Abstract][Full Text] [Related]
15. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
Constantinides A; Kappelle PJ; Lambert G; Dullaart RP
Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
[TBL] [Abstract][Full Text] [Related]
16. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
Simonen P; Stenman UH; Gylling H
Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
[TBL] [Abstract][Full Text] [Related]
17. Quantitative proteomic analysis of PCSK9 gain of function in human hepatic HuH7 cells.
Denis N; Palmer-Smith H; Elisma F; Busuttil A; Wright TG; Bou Khalil M; Prat A; Seidah NG; Chrétien M; Mayne J; Figeys D
J Proteome Res; 2011 Apr; 10(4):2011-26. PubMed ID: 21332221
[TBL] [Abstract][Full Text] [Related]
18. Effects of lipoprotein apheresis on PCSK9 levels.
Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
[TBL] [Abstract][Full Text] [Related]
19. Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement.
Henne KR; Ason B; Howard M; Wang W; Sun J; Higbee J; Tang J; Matsuda KC; Xu R; Zhou L; Chan JC; King C; Piper DE; Ketchem RR; Michaels ML; Jackson SM; Retter MW
J Pharmacol Exp Ther; 2015 Apr; 353(1):119-31. PubMed ID: 25653417
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
